Second- and third-line treatments in non-small cell lung cancer-Reference-Cited by-同舟云学术

Second- and third-line treatments in non-small cell lung cancer

Published:2006-02 Issue:1 Volume:7 Page:37-49
ISSN:1527-2729
Container-title:Current Treatment Options in Oncology
language:en
Short-container-title:Curr. Treat. Options in Oncol.

Author:

Kumar Atul,Wakelee Heather

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11864-006-0030-9.pdf

Reference59 articles.

1. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8–29.

2. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153–156.

3. Ettinger DS, Cox JD, Ginsberg RJ, et al.: NCCN Non-Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park) 1996, 10:81–111.

4. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J Clin Oncol 1996, 14:671–679.

5. Kelly K, Crowley J, Bunn PA Jr, et al.: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001, 19:3210–3218.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Controlling Cumulative Adverse Risk in Learning Optimal Dynamic Treatment Regimens;Journal of the American Statistical Association;2023-10-13

2. A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells;Pharmaceutics;2023-04-05

3. The Effect of the Kirsten Rat Sarcoma Viral Oncogene Homolog (Kras) Proto-Oncogene, GTPase Genetic Polymorphism on the Safety and Efficacy of Bevacizumab Combination Treatment Regimens for Patients with Nonsquamous, Non-Small Cell Lung Cancer with Brain Metastases;Genetic Testing and Molecular Biomarkers;2022-05-01

4. A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer;Lung Cancer;2022-01

5. Migration and invasion of NSCLC suppressed by the downregulation of Src/focal adhesion kinase using single, double and tetra domain anti- CEACAM6 antibodies;Translational Oncology;2021-07